DK1320355T3 - System til administration af en tobramycinformulering - Google Patents

System til administration af en tobramycinformulering

Info

Publication number
DK1320355T3
DK1320355T3 DK02771857T DK02771857T DK1320355T3 DK 1320355 T3 DK1320355 T3 DK 1320355T3 DK 02771857 T DK02771857 T DK 02771857T DK 02771857 T DK02771857 T DK 02771857T DK 1320355 T3 DK1320355 T3 DK 1320355T3
Authority
DK
Denmark
Prior art keywords
administering
less
tobramycin
aminoglycoside antibiotic
tobramycin formulation
Prior art date
Application number
DK02771857T
Other languages
Danish (da)
English (en)
Inventor
Robert J Speirs
Barbara A Schaeffler
Peter B Challoner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1320355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DK1320355T3 publication Critical patent/DK1320355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK02771857T 2001-05-18 2002-05-17 System til administration af en tobramycinformulering DK1320355T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18

Publications (1)

Publication Number Publication Date
DK1320355T3 true DK1320355T3 (da) 2006-07-31

Family

ID=23123791

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02771857T DK1320355T3 (da) 2001-05-18 2002-05-17 System til administration af en tobramycinformulering

Country Status (11)

Country Link
US (8) US20030143162A1 (enExample)
EP (2) EP2186508A3 (enExample)
JP (2) JP2004534763A (enExample)
AT (1) ATE322249T1 (enExample)
AU (1) AU2010210026A1 (enExample)
CA (1) CA2447600C (enExample)
DE (1) DE60210402T2 (enExample)
DK (1) DK1320355T3 (enExample)
ES (1) ES2261735T3 (enExample)
PT (1) PT1320355E (enExample)
WO (1) WO2002094217A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
CA2447600C (en) * 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
EP1458360B1 (en) * 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US20070071686A1 (en) * 2003-10-15 2007-03-29 Pari Gmbh Liquid preparation containing tobramycin
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
EP1729786A4 (en) * 2004-03-18 2008-03-26 Transave Inc ADMINISTRATION OF CISPLATIN BY INHALATION
ES2358024T3 (es) 2004-05-17 2011-05-04 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas.
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CA2570976C (en) 2004-06-18 2013-08-13 Novartis Vaccines And Diagnostics, Inc. Methods of treatment of endobronchial infections
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
CA2896083A1 (en) 2005-12-08 2007-06-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
US20110049634A1 (en) * 2008-04-02 2011-03-03 Nxp B.V. Method of manufacturing a semiconductor device and semiconductor device
CN102245195B (zh) * 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
EP3009442B1 (en) 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
BR112013000921A2 (pt) * 2010-07-12 2016-05-17 Xellia Pharmaceuticals Aps tratamento de infecções pulmonares pela administração de tobramicina por aerolização
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
JP2014523909A (ja) 2011-07-12 2014-09-18 カーディアス ファーマ コーポレイション 人工呼吸器関連肺炎（ｖａｐ）及び人工呼吸器関連気管（ｖａｔ）気管支炎の治療のためのアミカシンとホスホマイシンの組み合わせの製剤並びに方法及びシステム
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
JP6316846B2 (ja) 2013-01-11 2018-04-25 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ ポリミキシン含有組成物
HK1217665A1 (zh) * 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
KR102447412B1 (ko) 2014-05-15 2022-09-23 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
EP3166960B1 (en) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Low substituted polymyxins and compositions thereof
HUE052028T2 (hu) 2014-10-03 2021-04-28 Xellia Pharmaceuticals Aps Kompozíciók
ES2721401T3 (es) 2014-10-03 2019-07-31 Xellia Pharmaceuticals Aps Dispositivo de inhalación
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
ES2038445T3 (es) 1988-01-28 1993-07-16 Lameplast S.R.L. Tiras de ampollas para productos farmaceuticos, cosmeticos y otros.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
CZ20012147A3 (cs) * 1998-12-17 2003-01-15 Chiron Corporation Farmaceutický prostředek ve formě suchého práąku nebo rozpráąeného aerosolového prostředku pro léčení chronické bronchitidy
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Also Published As

Publication number Publication date
US20030143162A1 (en) 2003-07-31
EP2186508A3 (en) 2010-08-25
JP2009269923A (ja) 2009-11-19
AU2010210026A1 (en) 2010-09-02
US20120101055A1 (en) 2012-04-26
JP2004534763A (ja) 2004-11-18
EP1320355A1 (en) 2003-06-25
ES2261735T3 (es) 2006-11-16
EP1320355B1 (en) 2006-04-05
US20050207987A1 (en) 2005-09-22
US20040265241A1 (en) 2004-12-30
CA2447600C (en) 2015-10-20
WO2002094217A1 (en) 2002-11-28
US20080095717A1 (en) 2008-04-24
DE60210402D1 (de) 2006-05-18
DE60210402T2 (de) 2006-12-07
US7825095B2 (en) 2010-11-02
US20040131555A1 (en) 2004-07-08
US20110005518A1 (en) 2011-01-13
PT1320355E (pt) 2006-08-31
US6890907B2 (en) 2005-05-10
US20050201947A1 (en) 2005-09-15
EP2186508A2 (en) 2010-05-19
ATE322249T1 (de) 2006-04-15
CA2447600A1 (en) 2002-11-28
US8507454B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
DK1320355T3 (da) System til administration af en tobramycinformulering
CA2166312C (en) Compositions for nasal administration of desmopressin
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
TR199701170T1 (xx) Beklometazon dipropionat i�in �l��lm�� doz inhaleri.
MY144021A (en) Pharmaceutical delivery system
BR0109875A (pt) Tratamento de doenças respiratórias
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
CR6458A (es) Composiciones de valdecoxib
WO2004056314A3 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
GEP20053473B (en) High Potency Dihydroergotamine Compositions
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
RU2008142899A (ru) Композиции далбаванцина для лечения бактериальных инфекций
IL101056A (en) Composition for nasal treatment
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
DE69002718D1 (de) Medikamente.
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
CA2382887A1 (en) Immunopotentiating compositions
NO20041011L (no) Inhaleringssammensetninger omfattende tricykliske 5,6-dihydro-9H-pyrazolo(3,4-C) -1,2,4-triazolo(4,3-alfa)pyridiner
US20030158158A1 (en) Oct preparations
WO2002056867A3 (en) Extended release pharmaceutical compositions containing beta-lactam antibiotics
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use